Factor IX Inhibitor Evaluation, Plasma
Use
This test is useful for detecting and quantitating inhibitors to the specific coagulation factor requested, primarily factor IX, in patients with hemophilia B. It is not suitable for detecting lupus-like circulating anticoagulant inhibitors or nonspecific circulating anticoagulant inhibitors.
Special Instructions
Not provided.
Limitations
This test cannot detect lupus-like circulating anticoagulant inhibitors or nonspecific circulating anticoagulant inhibitors. Occasional potent lupus-like anticoagulants may cause false-positive readings for specific factor inhibitors.
New York Approved
Methodology
Other
Biomarkers
Factor IX
Protein
LOINC Codes
- 96459-3 - Fact IX Act + Inhib Pnl PPP
- 3187-2 - Fact IX Act/Nor PPP
- 69049-5 - Coagulation specialist review
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
3 mL in 3 plastic vials, each containing 1 mL
Minimum Volume
2 Plastic vials, each containing 1 mL
Container
Light-blue top (3.2% sodium citrate)
Collection Instructions
1. Specimen must be collected prior to factor replacement therapy. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again. Aliquot plasma (1-2 mL per aliquot) into 3 separate plastic vials, leaving 0.25 mL in the bottom of centrifuged vial. Freeze plasma immediately at -20 degrees C or, ideally, at -40 degrees C or below.
Patient Preparation
Fasting for 8 hours is preferred but not required. Patient must not be receiving Coumadin (warfarin) or heparin therapy.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |